A179530 Stock Overview
Develops and sells antibodies for livestock, fisheries, and humans in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ADBiotech Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,750.00 |
| 52 Week High | ₩5,680.00 |
| 52 Week Low | ₩2,390.00 |
| Beta | 0.81 |
| 11 Month Change | 16.82% |
| 3 Month Change | 23.36% |
| 1 Year Change | 3.02% |
| 33 Year Change | -60.86% |
| 5 Year Change | n/a |
| Change since IPO | -26.95% |
Recent News & Updates
Shareholder Returns
| A179530 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -5.2% | 5.1% | -0.5% |
| 1Y | 3.0% | 21.0% | 0.6% |
Return vs Industry: A179530 underperformed the KR Pharmaceuticals industry which returned 21% over the past year.
Return vs Market: A179530 exceeded the KR Market which returned 0.6% over the past year.
Price Volatility
| A179530 volatility | |
|---|---|
| A179530 Average Weekly Movement | 10.8% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in KR Market | 12.1% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A179530 has not had significant price volatility in the past 3 months.
Volatility Over Time: A179530's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 53 | Hong-Geo Jung | adbiotech.com |
ADBiotech Co., Ltd. develops and sells antibodies for livestock, fisheries, and humans in South Korea and internationally. The company offers antibiotic, disinfectant, helminthic, over the counter drugs, supplementary feed, and metabolic drugs. It also offers health functional and processed foods.
ADBiotech Co., Ltd. Fundamentals Summary
| A179530 fundamental statistics | |
|---|---|
| Market cap | ₩34.28b |
| Earnings (TTM) | -₩8.34b |
| Revenue (TTM) | ₩9.82b |
3.5x
P/S Ratio-4.1x
P/E RatioIs A179530 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A179530 income statement (TTM) | |
|---|---|
| Revenue | ₩9.82b |
| Cost of Revenue | ₩6.23b |
| Gross Profit | ₩3.60b |
| Other Expenses | ₩11.94b |
| Earnings | -₩8.34b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -912.60 |
| Gross Margin | 36.60% |
| Net Profit Margin | -84.91% |
| Debt/Equity Ratio | 229.3% |
How did A179530 perform over the long term?
See historical performance and comparison